In the European Group on Tumor Markers (EGTM) guidelines for the use of biomarkers in gastrointestinal cancer to screen colorectal cancer, preoperative CEA levels may be combined with clinical and histopathological criteria to determine the prognosis of patients with newly diagnosed CRC. This evidence concerns the gene CEACAM5 and neoplasm.